ArticleJournal of cancer research and clinical oncology2023

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Oliver Kraskowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.